as of —
₹—
Change
—
Day Open
₹—
Day High
₹—
Day Low
₹—
NSE Close — 25 Sep 2026
₹427.4
Change
-9.85 (-2.25%)
Open
₹440.0
Prev. Close
₹437.25
Day High
₹440.95
Day Low
₹425.0
Volume Analysis
Traded
212,626
Delivered
106,070
Delivery %
49.89%
End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.
Strengths, Weaknesses, Opportunities & Threats
Strengths (0)
No signal for this stock
Weaknesses (1)
- •Promoter holding is falling
Opportunities (0)
No signal for this stock
Threats (1)
- •FII holding has been falling
Rule-based signals from the fundamentals below — not investment advice.
Pivot Levels
| Type | R3 | R2 | R1 | Pivot | S1 | S2 | S3 |
|---|---|---|---|---|---|---|---|
| Classic | ₹453.19 | ₹447.07 | ₹437.24 | ₹431.12 | ₹421.29 | ₹415.17 | ₹405.34 |
| Fibonacci | ₹447.07 | ₹440.98 | ₹437.21 | ₹431.12 | ₹425.03 | ₹421.26 | ₹415.17 |
| Camarilla | ₹431.79 | ₹430.32 | ₹428.86 | ₹431.12 | ₹425.94 | ₹424.48 | ₹423.01 |
Support/resistance levels for today, calculated from the previous trading day's high/low/close.
Absolute Returns
YTD
+2.58%
1 Week
-1.86%
1 Month
+2.11%
3 Months
+13.1%
6 Months
+23.38%
1 Year
-9.05%
2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.
Stock Vitals
Computed from the latest available annual financials.
Graham Number
₹285.84
Current price is above the Graham Number — Benjamin Graham's estimate of fair value based on earnings and book value.
DuPont ROE Breakdown
11.81%
Net margin 7.13% × asset turnover 0.91x × equity multiplier 1.82x
Company Overview
Sector
Healthcare
Market Cap
₹3,991 Cr
P/E (TTM)
20.7
ROE
13.4%
Book Value
₹170.0
Face Value
₹10.0
Source: Screener.in (Consolidated figures) — data as of 25 Sep 2026. Not investment advice.
TopFund Analysis
Aarti Drugs Ltd. lands in the middle of the pack on TopFund's composite fundamentals check within the Healthcare sector, at 54/100. The strongest factor is Financial Strength (96/100), while Growth (12/100) is the weakest area to weigh before deciding. Notably: Promoter holding is falling. FII holding has been falling.
TopFund Score — Fundamentals Quality
54/100 — AverageData confidence: 79/100 (Moderate Confidence) — based on how complete and how fresh the underlying data is.
As of 27 Sep 2026 · How we calculate this →
Financial Strength
Growth
Valuation
Cash Flow
Corporate Governance
Momentum
Institutional Ownership
Business Quality
Risk & Volatility
Liquidity
From Screener.in
- −Stock is trading at 2.58 times its book value
- −Promoter holding has decreased over last quarter: -0.60%
- −The company has delivered a poor sales growth of 3.55% over past five years.
- −Company has a low return on equity of 13.3% over last 3 years.
Not investment advice — an automated read of public fundamentals data, for research context only.
Corporate Actions
FY2025-26 annual report; 41st AGM on Sept 26, 2026 via VC/OAVM.
41st AGM on September 26, 2026; FY 2025-26 annual report filed.
Aarti Drugs submitted its FY2025-26 Business Responsibility and Sustainability Report with the annual report and AGM notice.
Source: BSE regulatory filings, via Screener.in.
Quarterly Results
Last several quarters
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 661 | 642 | 606 | 620 | 555 | 598 | 557 | 677 | 591 | 653 | 602 | 720 | 703 |
| Expenses + | 577 | 565 | 536 | 534 | 490 | 531 | 495 | 583 | 516 | 569 | 547 | 624 | 605 |
| Operating Profit | 84 | 76 | 70 | 86 | 65 | 67 | 62 | 93 | 74 | 84 | 55 | 96 | 98 |
| OPM % | 13.0% | 12.0% | 12.0% | 14.0% | 12.0% | 11.0% | 11.0% | 14.0% | 13.0% | 13.0% | 9.0% | 13.0% | 14.0% |
| Other Income + | 1 | 1 | 2 | 1 | 1 | 1 | 12 | 2 | 0 | 0 | 1 | 1 | -1 |
| Interest | 9 | 8 | 8 | 9 | 9 | 9 | 9 | 9 | 9 | 8 | 9 | 8 | 9 |
| Depreciation | 13 | 13 | 13 | 14 | 13 | 14 | 14 | 15 | 15 | 16 | 18 | 18 | 18 |
| Profit before tax | 64 | 56 | 52 | 64 | 44 | 46 | 51 | 71 | 51 | 60 | 29 | 70 | 69 |
| Tax % | 24.0% | 30.0% | 29.0% | 26.0% | 24.0% | 24.0% | 27.0% | 12.0% | -6.0% | 25.0% | -40.0% | 21.0% | 28.0% |
| Net Profit + | 48 | 40 | 37 | 47 | 33 | 35 | 37 | 63 | 54 | 45 | 41 | 55 | 50 |
| EPS in Rs | 5 | 4 | 4 | 5 | 4 | 4 | 4 | 7 | 6 | 5 | 4 | 6 | 6 |
| Raw PDF | — | — | — | — | — | — | — | — | — | — | — | — | — |
Source: Screener.in — figures in ₹ Crores unless marked %.
Profit & Loss (Yearly)
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 1,097 | 1,140 | 1,195 | 1,244 | 1,561 | 1,806 | 2,155 | 2,489 | 2,716 | 2,529 | 2,387 | 2,565 | 2,678 |
| Expenses + | 925 | 960 | 1,005 | 1,042 | 1,350 | 1,541 | 1,714 | 2,156 | 2,407 | 2,208 | 2,097 | 2,254 | 2,344 |
| Operating Profit | 172 | 180 | 190 | 202 | 211 | 266 | 440 | 333 | 309 | 321 | 290 | 312 | 333 |
| OPM % | 16.0% | 16.0% | 16.0% | 16.0% | 14.0% | 15.0% | 20.0% | 13.0% | 11.0% | 13.0% | 12.0% | 12.0% | 12.0% |
| Other Income + | 1 | 0 | 4 | 1 | 6 | 6 | 5 | 11 | 2 | 4 | 16 | 2 | 1 |
| Interest | 42 | 48 | 40 | 38 | 44 | 37 | 26 | 24 | 37 | 38 | 39 | 36 | 34 |
| Depreciation | 31 | 37 | 38 | 40 | 43 | 49 | 50 | 50 | 50 | 51 | 56 | 67 | 71 |
| Profit before tax | 100 | 95 | 116 | 125 | 131 | 185 | 369 | 270 | 224 | 236 | 212 | 211 | 229 |
| Tax % | 23.0% | 28.0% | 29.0% | 34.0% | 32.0% | 24.0% | 24.0% | 24.0% | 26.0% | 27.0% | 21.0% | 8.0% | — |
| Net Profit + | 77 | 69 | 82 | 82 | 90 | 141 | 280 | 205 | 166 | 172 | 168 | 195 | 191 |
| EPS in Rs | 8 | 7 | 9 | 9 | 10 | 15 | 30 | 22 | 18 | 19 | 18 | 21 | 21 |
| Dividend Payout % | 41.0% | 24.0% | 3.0% | 3.0% | 3.0% | 3.0% | 8.0% | 5.0% | 6.0% | 5.0% | 5.0% | 9.0% | — |
Source: Screener.in — figures in ₹ Crores unless marked %.
Balance Sheet
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reserves | 284 | 333 | 376 | 432 | 520 | 629 | 820 | 944 | 1,100 | 1,190 | 1,278 | 1,458 |
| Borrowings + | 448 | 483 | 480 | 546 | 507 | 389 | 351 | 543 | 609 | 564 | 615 | 577 |
| Other Liabilities + | 248 | 261 | 311 | 388 | 405 | 535 | 502 | 629 | 620 | 587 | 591 | 690 |
| Total Liabilities | 1,004 | 1,102 | 1,191 | 1,389 | 1,455 | 1,576 | 1,766 | 2,208 | 2,421 | 2,432 | 2,575 | 2,815 |
| Fixed Assets + | 448 | 493 | 581 | 602 | 625 | 644 | 665 | 690 | 676 | 811 | 866 | 1,086 |
| CWIP | 16 | 34 | 14 | 28 | 33 | 12 | 19 | 77 | 210 | 261 | 330 | 214 |
| Investments | 5 | 5 | 12 | 11 | 12 | 13 | 17 | 19 | 19 | 20 | 22 | 27 |
| Other Assets + | 534 | 570 | 584 | 748 | 785 | 907 | 1,064 | 1,422 | 1,516 | 1,340 | 1,356 | 1,488 |
| Total Assets | 1,004 | 1,102 | 1,191 | 1,389 | 1,455 | 1,576 | 1,766 | 2,208 | 2,421 | 2,432 | 2,575 | 2,815 |
| Equity Capital | 24 | 24 | 24 | 24 | 24 | 23 | 93 | 93 | 93 | 92 | 91 | 91 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Cash Flow
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity + | 105 | 133 | 175 | 70 | 143 | 251 | 155 | 70 | 133 | 359 | 245 | 254 |
| Cash from Investing Activity + | -107 | -99 | -107 | -74 | -62 | -33 | -72 | -150 | -164 | -224 | -165 | -173 |
| Cash from Financing Activity + | 1 | -33 | -68 | 4 | -80 | -215 | -81 | 92 | 17 | -136 | -82 | -77 |
| Net Cash Flow | -1 | 1 | 0 | 0 | 1 | 2 | 2 | 13 | -14 | -1 | -2 | 3 |
| CFO/OP | 69 | 85 | 103 | 47 | 82 | 110 | 57 | 46 | 62 | 131 | 103 | 80 |
| Free Cash Flow | -2 | 34 | 68 | -5 | 80 | 214 | 78 | -82 | -31 | 133 | 67 | 80 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Shareholding Pattern
Quarter-by-quarter — Promoters, FII, DII & public holding trend
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Public | 33.78% | 35.16% | 34.3% | 34.01% | 34.01% | 33.58% | 32.57% | 32.58% | 32.7% | 32.71% | 33.19% | 33.76% |
| Promoters | 58.57% | 57.47% | 57.13% | 55.67% | 55.64% | 55.38% | 55.48% | 55.23% | 54.72% | 55.03% | 55.03% | 54.43% |
| FII | 2.33% | 2.1% | 2.56% | 2.95% | 2.5% | 2.28% | 2.25% | 2.26% | 2.68% | 2.15% | 1.57% | 1.52% |
| DII | 5.32% | 5.26% | 5.99% | 7.35% | 7.83% | 8.77% | 9.7% | 9.94% | 9.9% | 10.12% | 10.22% | 10.29% |
Source: Screener.in — quarterly shareholding disclosures.
Peers Comparison
Healthcare — ranked by market cap
| Company | Market Cap (Cr) | P/E | P/B | ROE |
|---|---|---|---|---|
| Aarti Drugs Ltd. (this stock) | 3,991 | 20.7 | 2.57 | 13.4% |
| Unichem Laboratories Ltd | 3,870 | 31.7 | 1.42 | 3.17% |
| Kwality Pharmaceuticals L | 3,824 | 46.8 | 11.48 | 22.6% |
| Gufic Biosciences Ltd. | 4,237 | 57.7 | 6.37 | 10.1% |
| Solara Active Pha Sci Ltd | 3,587 | 840.0 | 2.14 | -0.13% |
| Sms Pharmaceuticals Ltd. | 4,448 | 43.4 | 5.66 | 14.3% |
| Ind Swift Laboratories Lt | 3,489 | 53.6 | 2.52 | 3.87% |
Which Mutual Funds Hold Aarti Drugs Ltd.?
Frequently Asked Questions about Aarti Drugs Ltd.
Aarti Drugs Ltd. (AARTIDRUGS) closed at ₹427.4 on NSE on 25 September 2026, down 9.85 (2.25%) from the previous close.
Aarti Drugs Ltd. trades on the NSE (National Stock Exchange of India) under the symbol AARTIDRUGS.
Aarti Drugs Ltd. has a trailing twelve-month P/E (price-to-earnings) ratio of 20.7.
Aarti Drugs Ltd. has a dividend yield of 0.46%.
Aarti Drugs Ltd.'s 52-week high is ₹534.0 and its 52-week low is ₹319.0.
Aarti Drugs Ltd. has a market capitalisation of ₹3,991 crore.
Aarti Drugs Ltd. has a TopFund Quality Score of 54/100 (Average), a composite of profitability, balance-sheet health, growth and valuation. This is an analytical score based on public data, not personalized investment advice — see the full breakdown below before deciding.
Community Sentiment
What are other investors saying about Aarti Drugs Ltd.?
No votes yet — be the first to share your view.
Sign in to voteDiscussion
User-generated content — not investment advice, and not verified or endorsed by TopFund.
Sign in to join the discussionNo comments yet — start the discussion.